Merck Sharp & Dohme Corp (NYSE:MRK) Sentiment Report

Merck & Co., Inc. (NYSE:MRK) Logo

Sentiment for Merck Sharp & Dohme Corp (NYSE:MRK)

Merck Sharp & Dohme Corp (NYSE:MRK) institutional sentiment is 1 in 2018 Q2. Its the same as in 2018Q1. The ratio is neither negative nor positive, as only 656 investment professionals increased or opened new positions, while 656 sold and trimmed stakes in Merck Sharp & Dohme Corp. The investment professionals in our partner’s database now possess: 1.88 billion shares, down from 1.91 billion shares in 2018Q1. Also, the number of investment professionals holding Merck Sharp & Dohme Corp in their top 10 positions increased from 56 to 82 for an increase of 26. Sold All: 48 Reduced: 608 Increased: 530 New Position: 126.

Merck & Co., Inc. provides healthcare solutions worldwide. The company has market cap of $192.66 billion. It operates in four divisions: Pharmaceutical, Animal Health, Healthcare Services, and Alliances divisions. It has a 152.76 P/E ratio. The firm offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

The stock decreased 0.70% or $0.52 during the last trading session, reaching $74.09. About 9.26 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 6.72% since November 14, 2017 and is uptrending. It has underperformed by 8.90% the S&P500.

Senzar Asset Management Llc holds 18.82% of its portfolio in Merck & Co., Inc. for 107,434 shares. Srb Corp owns 1.88 million shares or 12.53% of their US portfolio. Moreover, Sector Gamma As has 9.22% invested in the company for 913,830 shares. The New York-based Healthcor Management L.P. has invested 8.06% in the stock. Krensavage Asset Management Llc, a New York-based fund reported 515,428 shares.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Ratings analysis reveals 100% of Merck \u0026 Co’s analysts are positive. Out of 7 Wall Street analysts rating Merck \u0026 Co, 7 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $74 while the high is $84. The stock’s average target of $79 is 6.63% above today’s ($74.09) share price. MRK was included in 9 notes of analysts from July 30, 2018. The firm earned “Overweight” rating on Friday, October 12 by Barclays Capital. As per Thursday, October 11, the company rating was maintained by Credit Suisse. The rating was maintained by Bank of America with “Buy” on Monday, July 30. The firm has “Overweight” rating by Morgan Stanley given on Thursday, August 23. SunTrust maintained the shares of MRK in report on Monday, October 29 with “Buy” rating. Barclays Capital maintained Merck & Co., Inc. (NYSE:MRK) on Friday, September 7 with “Overweight” rating. The firm has “Outperform” rating by BMO Capital Markets given on Monday, October 22. As per Wednesday, October 31, the company rating was maintained by Citigroup. Citigroup maintained the shares of MRK in report on Tuesday, October 16 with “Buy” rating.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Streetinsider.com which released: “Merck (MRK) Begins Rolling Submission of Licensure Application for V920 to FDA” on November 13, 2018, also Streetinsider.com with their article: “Merck (MRK) Reports Phase 3 KEYNOTE-181 Trial Investigating KEYTRUDA Met a Primary Endpoint of OS in Patients …” published on November 14, 2018, Seekingalpha.com published: “OncoSec down 56% premarket on mid-stage TAVO data” on November 06, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Seekingalpha.com and their article: “Merck’s cancer candidates MK-4280 and MK-7684 show encouraging action in early-stage studies” published on November 07, 2018 as well as Finance.Yahoo.com‘s news article titled: “Can These 2 Battered Biotech Stocks Recover?” with publication date: November 14, 2018.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.